Seroquel XR 400mg Tablet is used to treat schizophrenia, bipolar disorder, and major depressive disorder, as part of a total treatment plan that includes psychological and lifestyle treatments. Seroquel XR 400mg Tablet may help reduce hallucinations, delusions, and manic and depressive episodes in patients with these conditions. It is also used to treat bipolar disorder in elderly patients. Dosing for Seroquel XR 400mg Tablet is based on your medical condition.
Seroquel XR 400mg Tablet may also be used for other purposes not listed in this information. Please refer to the list of drugs for which there is an online sales pitch.
Do not take Seroquel XR 400mg Tablet if you are allergic to any of the components, or if you are taking any of the components. Before taking Seroquel XR 400mg Tablet inform your doctor if you have had an allergic reaction to any of the components in Seroquel XR 400mg Tablet or any of the inactive ingredients in Seroquel XR 400mg Tablet.
Seroquel XR 400mg Tablet may cause drowsiness, dizziness, lightheadedness, or headache. Do not drive, use machinery, or do anything that may be dangerous you may feel tired, sleepy, or dizzy for at least 4 hours after you take Seroquel XR 400mg Tablet. Your doctor may need to slowly lower your blood pressure to normal before you feel better. If you must take Seroquel XR 400mg Tablet after meals you may notice drowsiness, tiredness, lightheadedness, headache, or trouble breathing. Your blood pressure may get up from a sitting or lying position. Your blood pressure may drop. Your muscle tone may become short or become muscle pain may occur. Tell your doctor if you are having surgery. You may take Seroquel XR 400mg Tablet with food if it is having surgery.
The most common side effects of Seroquel XR 400mg Tablet are nausea, diarrhea, stomach pain, stomach cramps, feeling sick, headache, sleep problems, or a stuffy nose. Tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding.
Read the Patient Information Leaflet if available from your pharmacist before you start taking Seroquel XR 400mg Tablet and each time you get a refill. If you have any questions, ask your doctor or pharmacist.ABbrevia (Quetiapine)10 mg/5 mL, 150 mg/300 mg, 300 mg/400 mg, 600 mg/800 mg, 1000 mg/400 mgBrand Name(s may also be called Quetiapine brand names)LicenseProduct Name(s) (in millions) Brand name(s) (in thousands) Generic name(s) (in thousands) No. of brand(s) of each productSEROQUEL XR 400mg Tablet is used to treat schizophrenia, bipolar disorder, and major depressive disorder as part of a total treatment plan that includes psychological and lifestyle treatments. Seroquel XR 400mg Tablet may also be used for the purposes only listed above. You may not use it for more than 12 weeks at a time in any of the conditions listed above.
Seroquel (quetiapine) is a non-stimulant medication classified as a second-generation antipsychotic drug (). As a first-generation antipsychotic, Seroquel has been studied for its efficacy and safety in treating schizophrenia and bipolar disorder (). The efficacy of Seroquel in improving symptoms of schizophrenia in acute manic episodes was demonstrated by the first-line treatment of the acute phase of manic episodes associated with bipolar I disorder ().
The use of antipsychotic medications can have various consequences for the health of individuals. Although Seroquel is primarily indicated to treat schizophrenia, the clinical use of antipsychotic medications is often limited for the treatment of bipolar depression (). The acute phase of bipolar depression is characterized by depressive episodes that occur from time to time, and the efficacy of antipsychotic medications in reducing depressive symptoms has not been well established (). Therefore, the efficacy of antipsychotic medications in the acute phase of bipolar depression is poorly established. As a result, many studies have demonstrated the efficacy of antipsychotic medications in the acute phase of bipolar depression (). A meta-analysis by Sato et al. () showed that the mean change in the Hamilton Depression Rating Scale for Borderline Anxiety score was 3.3 (95% CI 1.3 to 6.1) in the first-line treatment for bipolar depression, and 3.6 (95% CI 2.1 to 5.1) in the second-line treatment (). The results of the meta-analysis indicate that the mean change in the Hamilton Depression Rating Scale for Borderline Anxiety score was 3.7 (95% CI 2.2 to 7.9) in the first-line treatment and 4.8 (95% CI 4.1 to 6.4) in the second-line treatment ().
The objective of this study was to assess the efficacy of Seroquel in the acute phase of bipolar depression and to determine the effect of aripiprazole, an antipsychotic medication, on the change in the Hamilton Depression Rating Scale for Borderline Anxiety score in acute bipolar depression patients. A total of 1,853 acute bipolar depression patients were enrolled from an acute treatment center in Japan. The patients were randomized to receive Seroquel (60 mg daily) or placebo for 60 days. The change in the Hamilton Depression Rating Scale for Borderline Anxiety score in the acute treatment group was significantly lower than that in the placebo treatment group (4.8 points for Seroquel vs. 3.3 points for placebo) (), and the effect of the change in the Hamilton Depression Rating Scale for Borderline Anxiety score on the change in the Hamilton Depression Rating Scale for Borderline Anxiety was significant with a significant difference (p<0.05). The mean change in the Hamilton Depression Rating Scale for Borderline Anxiety score in the acute treatment group was 5.9 (95% CI 4.6 to 7.3), and the change in the Hamilton Depression Rating Scale for Borderline Anxiety score was −5.5 (−8.6 to +0.6) in the placebo group (). The mean change in the Hamilton Depression Rating Scale for Borderline Anxiety score in the placebo group was −2.2 (−1.9 to 0.2) and −2.3 (−1.8 to 0.1) in the Seroquel and placebo groups, respectively. The effect of Seroquel on the change in the Hamilton Depression Rating Scale for Borderline Anxiety was not significant between the two treatment groups ().
The results of the study demonstrated that Seroquel significantly reduced the change in the Hamilton Depression Rating Scale for Borderline Anxiety score in the acute treatment group and decreased the change in the Hamilton Depression Rating Scale for Borderline Anxiety score in the placebo group ().
The study was funded by the National Institute of Mental Health and the National Institute of Dementia and Mental Illness (). The authors declare no conflicts of interest relevant to the work reported in this article.
The change in the Hamilton Depression Rating Scale for Borderline Anxiety scale was calculated by using the Hamilton Rating Scale for Borderline Anxiety as the primary outcome. The change in the Hamilton Rating Scale for Borderline Anxiety score in the acute treatment group was significantly lower than that in the placebo treatment group (1.8 points for Seroquel vs. 3.4 points for placebo). The effect of Seroquel on the change in Hamilton Rating Scale for Borderline Anxiety score in the placebo group was significant with a significant difference (p<0.05).
A significant difference was demonstrated in the change in the Hamilton Depression Rating Scale for Borderline Anxiety score in the acute treatment group and in the placebo treatment group (1.
Interactions between drugs may change how the body absorbs or excreted some medications. Some medications that may interact with Seroquel include:
Dosage form:Tablets
Interactions note:There may be interactions between Seroquel (quetiapine) and amitriptyline (amoxil).
Inform Drug Safety Unit:For medical and scientific advice, contact medical director or prescribing representative.
Medication interactions can occur because drugs interact differently with different body systems. The following information describes potential interactions, and information can be obtained from your healthcare provider:
Drug interactions:
Seroquel (quetiapine) and amitriptyline (amoxil) may have some interactions with certain drugs. These drugs are sometimes prescribed for conditions that may affect the central nervous system, including:
Seroquel (quetiapine) may also interact with certain antibiotics. These antibiotics include:
Certain antifungals, including ketoconazole and itraconazole, may also interact with Seroquel (quetiapine).
Certain drugs can increase the levels of Nitazoxanide (an antibiotic that prevents the breakdown of amoxicillin).
Certain drugs can increase the levels of a drug's breakdown products.
Interaction with other medications
Seroquel (quetiapine fumarate) is a type of drug that was approved by the FDA in March 2000 for the treatment of schizophrenia. However, it was originally marketed to treat bipolar disorder and certain other mental illnesses such as depression. Seroquel was approved by the US Food and Drug Administration (FDA) in 2007 as a second-line treatment for bipolar disorder. It is available in two forms:
In June 2015, the manufacturer of Seroquel (quetiapine fumarate) announced that it had entered into an agreement with Pfizer, a pharmaceutical company that manufactures and markets the generic version. The agreement provides for a 30-day supply of the generic version, which will expire in July 2018. However, generic versions of Seroquel will be available at a lower price point, and the company has not yet made any announcement about their availability until that time. In addition, the generic version will also have a 30-day supply, which will be available to the public in three different strengths: 10 mg, 20 mg and 30 mg. This agreement will expire in July 2018.
On March 1, 2022, Merck & Company, the manufacturer of Seroquel (quetiapine fumarate), announced that it had entered into an agreement with Johnson & Johnson for a license for the commercial distribution of the generic version of Seroquel (quetiapine fumarate) in the United States. This agreement provides for a 30-day supply of the commercial version of Seroquel (quetiapine fumarate) and a 90-day supply of the generic version of Seroquel (quetiapine fumarate). This agreement will expire in the third quarter of 2024.
In September 2022, the FDA approved the first clinical trial for the treatment of schizophrenia. The study was designed to evaluate the safety and efficacy of the schizophrenia treatment in patients with schizophrenia. This trial has been conducted in 823 subjects, of which 295 were treated with Seroquel (quetiapine fumarate) at doses of 2.5 mg to 5 mg and in the acute treatment phase of schizophrenia (two times higher than the usual dose of Seroquel).
This is a single-center, non-interventional, placebo-controlled, single-blind, multicentre study, conducted by the University of Illinois School of Medicine, to evaluate the safety and efficacy of Seroquel (quetiapine fumarate) in patients with schizophrenia (schizophrenia, Bipolar Disorder and other mood disorders) and bipolar disorder (manic-depressive disorder, manic-depressive disorder and mixed-depressive disorder).
The primary efficacy end point was the change from baseline in the change from baseline in the change from baseline from baseline from baseline. The primary safety endpoint was change from baseline from baseline from baseline from baseline at 1 year. Secondary end points included change from baseline to month 12. Safety was evaluated using the primary and secondary end points, respectively. The primary safety end points were the number needed to treat (NNT) and the incidence of adverse events (AEs). The incidence of NNT was calculated as the difference between the number of patients with NNT and the number of patients with the expected number of events (NNT) and the expected number of AEs (AEs).
In the current study, the use of Seroquel (quetiapine fumarate) at doses greater than 2.5 mg for treatment of acute manic-depressive disorder and for the treatment of bipolar disorder was associated with an increased incidence of NNT and AEs.
Stade de France Pharmacy